Tectonic Therapeutic, Inc. (TECX)
NasdaqGM · USD · Healthcare · Biotechnology
$20.09 (+0.70%) as of
Key statistics
- Market cap
- 392.75M
- Forward P/E
- -4.22
- EPS (TTM)
- -4.57
- Dividend yield
- 0.00%
- 52-week range
- 15.52 – 39.53
- Beta
- 0.38
- Profit margin
- 0.00%
- Analyst target
- $71.00
- Volume
- 6.15k
About Tectonic Therapeutic, Inc.
Tectonic Therapeutic, Inc., a biotechnology company, focuses on the discovery and development of therapeutic proteins and antibodies to modulate the activity of G protein coupled receptors (GPCRs). It develops GEODe technology platform to enable the discovery and development of GPCR-targeted biologic medicines. The company's lead product is TX45, a Fc-relaxin fusion molecule that activates the RXFP1 receptor, the GPCR target of the hormone, and relaxin. It is also developing TX2100 for the treatment of hereditary hemorrhagic telangiectasia; GPCR modulator bispecific for treating fibrosis; and other GPCR modulators. The company is headquartered in Watertown, Massachusetts.
- Sector
- Healthcare
- Industry
- Biotechnology
- Headquarters
- Watertown, MA, United States
- Employees
- 60
Financial statements (income statement, balance sheet, cash flow) and an interactive price chart are available on this page with JavaScript enabled.